Comparative Pharmacology
Head-to-head clinical analysis: CYTOVENE versus DOCOSANOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOVENE versus DOCOSANOL.
CYTOVENE vs DOCOSANOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanosine analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporation into viral DNA, causing chain termination. It is phosphorylated intracellularly to ganciclovir triphosphate, which is active against cytomegalovirus (CMV).
Docosanol is a saturated fatty alcohol that inhibits fusion between the host cell plasma membrane and the herpes simplex virus envelope, thereby preventing viral entry and replication.
Induction: 5 mg/kg IV every 12 hours for 14-21 days; maintenance: 5 mg/kg IV once daily for 7 days per week or 6 mg/kg IV once daily for 5 days per week
Apply a thin layer of 10% cream to affected area 5 times daily until healing is complete, typically 4-6 days.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 28-40 hours in severe renal impairment (CrCl <10 mL/min)
Due to negligible systemic absorption, a terminal elimination half-life is not defined for topical docosanol. In vitro studies of hepatic metabolism suggest a plasma half-life of approximately 1 hour if systemically absorbed, but clinical relevance is absent.
Primarily renal excretion as unchanged drug (>90%); 1-2% biliary/fecal
Docosanol is a topical agent with negligible systemic absorption; no significant renal or fecal elimination occurs after topical application. In animal studies, less than 1% of a topical dose was excreted in urine or feces as unchanged drug or metabolites.
Category C
Category C
Antiviral Agent
Antiviral Agent